Bone Density Clinical Trials

A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis

The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population is patients with NASH and compensated cirrhosis, between the ages of 18-75.

A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population is patients with NASH and F3 fibrosis, between the ages of 18-75.

Bone Water and Mineralization Measured by Nuclear Magnetic Resonance

All subjects meeting the enrollment criteria at screening will receive bone mineral density scans of the lumbar vertebrae (lateral and AP) and proximal femur quantified by DXA and 3D bone mineral density scans of the mid-shaft tibia by pQCT and acquisition of MR images of the left mid-shaft tibia.

MRI Assessment of Hip Fracture Risk and Therapy Response in HIV/HCV Coinfection

., hip) in three patient cohorts available through a recently funded NIH project in order to determine how MRI analyzes bone deficits inaccessible by BMD/FRAX scores, how the methodology may provide clinical tools useful for future HIV+/HCV+ trials, and how direct-acting antiviral (DAA) treatment of HCV affects bone strength in …

None

None

None

None

None

None